On March 13, 2025, David Altshuler, Executive Vice President and Chief Scientific Officer at Vertex Pharmaceuticals Inc, sold 3,231 shares of the company. Following this transaction, the insider now owns 23,281 shares of Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc (VRTX, Financial) is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company focuses on developing and commercializing therapies for cystic fibrosis and has a robust pipeline of investigational small molecule medicines in other serious diseases.
Over the past year, David Altshuler has sold a total of 9,708 shares and has not purchased any shares. The insider transaction history for Vertex Pharmaceuticals Inc shows that there have been 0 insider buys and 45 insider sells over the same timeframe.
As of the date of the recent sale, shares of Vertex Pharmaceuticals Inc were trading at $510 each, giving the stock a market cap of $130,295.720 million. The stock's GF Value is estimated at $421.70, resulting in a price-to-GF-Value ratio of 1.21. This indicates that the stock is modestly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on the following three factors:
- Historical multiples (price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow) that the stock has traded at.
- A GuruFocus adjustment factor based on the company’s past returns and growth.
- Future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
